The immuno-oncology race: myths and emerging realities

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: The number of broad programmes for leading PD1/PDL1 players across indications: white space is disappearing.
Figure 2: Immuno-oncology combination trials being pursued by leading companies.


The authors gratefully acknowledge the contributions of U. Schulze, P. Tollman and L. Henry to this work.

Author information



Corresponding author

Correspondence to Valery Panier.

Ethics declarations

Competing interests

The authors of this article are employees of The Boston Consulting Group (BCG), a management consultancy that works with the world's leading biopharmaceutical companies on strategies in oncology, among other therapeutic areas. The research for this specific article was funded by BCG's Health Care practice.

Supplementary information

Supplementary information S1 (box)

Dataset and analysis methods (PDF 102 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cavnar, S., Valencia, P., Brock, J. et al. The immuno-oncology race: myths and emerging realities. Nat Rev Drug Discov 16, 83–84 (2017).

Download citation

Further reading